Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV feasibility study of benzydamine mouthwash for radiation-induced oral mucositis in head and neck cancer
2020-003306-32Phase 4Completed
- Sponsor
- Angelini Pharma
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benzydamine in stomatitis and head and neck cancer (HNC), sponsored by Angelini Pharma. Primary endpoint: Responder rate for oral mucositis pain. Started Nov 2020; status: completed.
02
Drugs
benzydamine
03
Conditions
stomatitishead and neck cancer (HNC)
Beyond the preview
Go deeper on 2020-003306-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003306-32.